Fabre N - Search Results

1

Fabre N, Brefel-Courbon C, Rascol O. Fabre N, et al. Rev Prat. 1997 May 15;47(10):1077-82. Rev Prat. 1997. PMID: 9208670 French.

2

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.

Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, Agid Y. Rascol O, et al. Among authors: fabre n. Mov Disord. 2001 Jul;16(4):708-13. doi: 10.1002/mds.1143. Mov Disord. 2001. PMID: 11481696 Clinical Trial.

3

Does ageing influence deep brain stimulation outcomes in Parkinson's disease?

Ory-Magne F, Brefel-Courbon C, Simonetta-Moreau M, Fabre N, Lotterie JA, Chaynes P, Berry I, Lazorthes Y, Rascol O. Ory-Magne F, et al. Among authors: fabre n. Mov Disord. 2007 Jul 30;22(10):1457-1463. doi: 10.1002/mds.21547. Mov Disord. 2007. PMID: 17516457 Clinical Trial.

4

Do Parkinson's disease patients disclose their adverse events spontaneously?

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Montastruc JL, Rascol O. Perez-Lloret S, et al. Among authors: fabre n. Eur J Clin Pharmacol. 2012 May;68(5):857-65. doi: 10.1007/s00228-011-1198-x. Epub 2011 Dec 29. Eur J Clin Pharmacol. 2012. PMID: 22205275

5

Factors related to orthostatic hypotension in Parkinson's disease.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM, Pavy-Le Traon A, Montastruc JL, Rascol O. Perez-Lloret S, et al. Among authors: fabre n. Parkinsonism Relat Disord. 2012 Jun;18(5):501-5. doi: 10.1016/j.parkreldis.2012.01.012. Epub 2012 Feb 13. Parkinsonism Relat Disord. 2012. PMID: 22336566

6

Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, Rascol O. Perez-Lloret S, et al. Among authors: fabre n. Clin Neuropharmacol. 2012 Nov-Dec;35(6):261-5. doi: 10.1097/WNF.0b013e31826e6e6d. Clin Neuropharmacol. 2012. PMID: 23123689

7

Deep brain stimulation for parkinson's disease: correlation between intraoperative subthalamic nucleus neurophysiology and most effective contacts.

Cintas P, Simonetta-Moreau M, Ory F, Brefel-Courbon C, Fabre N, Chaynes P, Sabatier J, Sol JC, Rascol O, Berry I, Lazorthes Y. Cintas P, et al. Among authors: fabre n. Stereotact Funct Neurosurg. 2003;80(1-4):108-13. doi: 10.1159/000075169. Stereotact Funct Neurosurg. 2003. PMID: 14745218 Clinical Trial.

8

CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.

Rascol O, Fabre N, Teräväinen H, Poewe W, Lücking C, Rinne U, Dupont E, Hirt D, Hoyer M, Lataste X. Rascol O, et al. Among authors: fabre n. Clin Neuropharmacol. 1990 Aug;13(4):303-11. Clin Neuropharmacol. 1990. PMID: 2208182 Clinical Trial.

9

Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease.

Rascol O, Sabatini U, Fabre N, Senard JM, Simonetta-Moreau M, Montastruc JL, Clanet M, Rascol A. Rascol O, et al. Among authors: fabre n. Mov Disord. 1995 Mar;10(2):163-70. doi: 10.1002/mds.870100206. Mov Disord. 1995. PMID: 7753058

10

Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.

Rascol O, Fabre N, Blin O, Poulik J, Sabatini U, Senard JM, Ané M, Montastruc JL, Rascol A. Rascol O, et al. Among authors: fabre n. Mov Disord. 1994 Jul;9(4):437-40. doi: 10.1002/mds.870090410. Mov Disord. 1994. PMID: 7969211 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters